Urogen Pharma Ltd. (URGN)
NASDAQ · Healthcare
Urogen Pharma Ltd. Operating Income 2016–2025
Urogen Pharma Ltd. annual/quarterly operating income history and growth rate from 2016 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Urogen Pharma Ltd. operating income for the quarter ending March 31, 2026 was -20.3 M, a 45.11% decrease year-over-year.
- Urogen Pharma Ltd. operating income for the twelve months ending March 31, 2026 was -126.0 M, a 52.51% increase year-over-year.
- Urogen Pharma Ltd. annual operating income for 2025 was -124.9 M, a 29.01% increase from 2024.
- Urogen Pharma Ltd. annual operating income for 2024 was -96.8 M, a 47.68% increase from 2023.
- Urogen Pharma Ltd. annual operating income for 2023 was -65.5 M, a 17.09% decrease from 2022.
- Urogen Pharma Ltd. annual operating income for 2022 was -79.0 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Urogen Pharma Ltd. Operating Income — FAQ
Urogen Pharma Ltd. (URGN) operating income over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
What is Urogen Pharma Ltd.'s operating income?
Urogen Pharma Ltd. (URGN) reported operating income of -$125M for fiscal 2025.
Where can I see URGN's operating income history?
The chart and table above show Urogen Pharma Ltd.'s operating income by year and by quarter, including the growth rate.